Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- -3.60 --
08/04/2022 -- Results Q2 2022 -5.56 -4.01 -38.72%
05/05/2022 -- Results Q1 2022 -4.24 -4.47 5.23%
02/25/2022 -- Results Q4 2021 -6.16 -3.83 -60.82%
11/04/2021 -- Results Q3 2021 -4.46 -4.70 5.11%
08/05/2021 -- Results Q2 2021 -5.23 -3.99 -31.14%
05/06/2021 -- Results Q1 2021 0.69 -1.65 141.7%
02/25/2021 -- Results Q4 2020 -5.20 -4.22 -23.13%
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -28.23%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
URL https://www.beigene.com
Investor Relations URL https://ir.beigene.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
221.9%
43.53%
18.18%
55.88%
4.85%
-49.38%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
9.85%
94.51%
-12.52%
-8.25%
1.17%
-31.36%
-37.82%
-9.23%
--
--
--
--
--
-54.14%
-44.48%
-62.60%
--
--
--
--
--
--
--
-88.33%
--
--
--
--
-43.61%
-9.85%
-38.80%
-47.71%
As of October 03, 2022.

Profile

Edit
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
URL https://www.beigene.com
Investor Relations URL https://ir.beigene.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CHIH 525424.0 USD 6.59%
REFGX 52.27M USD 3.48%
KURE 2.908M USD 3.32%
CNCR 651760.0 USD 3.10%
CDWFX 62.93M USD 2.90%
MPACX 26.30M USD 2.87%
BBH 7.865M USD 1.85%
POAGX 116.54M USD 1.63%
POGRX 108.36M USD 1.53%
HQL 5.703M USD 1.17%
IBB 86.86M USD 1.15%
CIF1836 3.373M USD 1.14%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BGNE Tweets